Compounded Semaglutide vs Compounded Tirzepatide: Which Should You Choose in 2026?

Two of the most discussed medications in weight management today are semaglutide and tirzepatide. Both are available as compounded formulations through licensed telehealth providers like CoraDoc. But they work differently, have different price points, and may suit different patients. This guide walks through both options so you can have an informed conversation with your provider.

How Each Medication Works

Compounded Semaglutide contains semaglutide as the active pharmaceutical ingredient. Semaglutide is a GLP-1 receptor agonist, meaning it mimics the glucagon-like peptide-1 hormone to help regulate appetite, slow gastric emptying, and support blood sugar regulation. It activates a single receptor pathway.

Compounded Tirzepatide contains tirzepatide as the active pharmaceutical ingredient. Tirzepatide is a dual GIP and GLP-1 receptor agonist, activating two hormone pathways simultaneously — the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-action mechanism is thought to contribute to its distinct metabolic effects.

Neither Compounded Semaglutide nor Compounded Tirzepatide is FDA-approved. Both are prepared by licensed 503A-compliant U.S. compounding pharmacies and dispensed only with a valid individual prescription following medical evaluation.

What Does the Research Show?

Clinical research on the branded versions of these medications provides context — though individual results from compounded formulations may vary.

In the landmark STEP-1 trial published in the New England Journal of Medicine, participants receiving once-weekly semaglutide 2.4mg experienced a mean body weight reduction of approximately 14.9% over 68 weeks, compared to 2.4% with placebo. (Source: NEJM, 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/)

In the SURMOUNT-5 trial published in 2025, tirzepatide demonstrated greater average weight reduction compared to semaglutide in a head-to-head comparison among participants with obesity but without type 2 diabetes — with tirzepatide achieving approximately 20.2% mean weight reduction versus 13.7% with semaglutide at 72 weeks. (Source: NEJM, 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/)

These figures reflect branded, FDA-approved formulations used in controlled clinical trials. Your licensed CoraDoc provider will work with you to set realistic goals based on your individual health profile. Individual results vary.

How Do the Side Effects Compare?

Both medications share similar side effect profiles, primarily gastrointestinal: nausea, constipation, and occasional vomiting — particularly during dose escalation. These are typically mild to moderate and improve as your body adjusts. CoraDoc providers use a gradual titration approach — starting low and increasing your dose at your pace — to help minimize side effect severity.

Pricing Comparison at CoraDoc

Compounded Semaglutide: from $165/month (3-month program) or $99/month (6-month program)
Compounded Tirzepatide: from $232/month (3-month program) or $149/month (6-month program)

Both programs include CoraDoc’s Triple Free Promise: free licensed provider consultation, free 2-day shipping via DIRX pharmacy, and free supplies. One-time payment — no membership fees, no recurring charges.

Which One Is Right for You?

The right medication for your individual situation is determined by your licensed CoraDoc provider following a full review of your medical history, current medications, BMI, and health goals. There is no single answer that applies to every patient. Your provider will discuss both options with you and recommend the most appropriate program based on your individual health profile.